Human Bleomycin Hydrolase (BLMH) Enzyme
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Description
Bleomycin Hydrolase is a recombinant enzyme.
Documents del producto
Product specifications
| Category | Proteins and Peptides |
| Immunogen Target | Bleomycin Hydrolase (BLMH) |
| Host | E. coli |
| Recommended Dilution | Optimal dilutions/concentrations should be determined by the end user. |
| Origin | Human |
| Expression | Recombinant |
| Purity | > 90% (SDS-PAGE) |
| Size 1 | 5 µg |
| Size 2 | 20 µg |
| Size 3 | 1 mg |
| Form | Liquid |
| Tested Applications | SDS-PAGE |
| Availability | Shipped within 5-10 working days. |
| Storage | Store at 4°C if the entire vial will be used within 2 weeks. Store at -20 °C for long term storage. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | Q13867 |
| Background | Protein BLMH |
| Status | RUO |
| Note | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION. |
Descripción
Related Products
BLMH antibody
Bleomycin hydrolase (BMH) is a cytoplasmic cysteine peptidase that is highly conserved through evolution; however, the only known activity of the enzyme is metabolic inactivation of the glycopeptide bleomycin (BLM), an essential component of combination chemotherapy regimens for cancer. The protein contains the signature active site residues of the cysteine protease papain superfamily.
Ver Producto
Recombinant Human BLMH
Ver Producto
Bleomycin Hydrolase (BLMH) Antibody
The normal physiological role of BLM hydrolase is unknown, but it catalyzes the inactivation of the antitumor drug BLM (a glycopeptide) by hydrolyzing the carboxamide bond of its B-aminoalaninamide moiety thus protecting normal and malignant cells from BLM toxicity (By similarity).
Ver Producto